China is a one of the most important regions for the booming obesity market, thanks to government incentives and changing ...

We are on the cusp of turning the tide against dementia — which makes this an especially bad time to pull back on research.” ...

The FDA is launching a program to reward companies with accelerated drug review and speedy agency feedback, if their actions ...

Kraft Heinz will be pulling artificial dyes from its U.S. products starting in 2027 and will no longer roll out new products ...

Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.

The Medicare pay bump for doctors that was part of the House version of Republicans’ tax bill was dropped in the Senate’s ...

Historically, ACIP has been one of the most transparent federal committees, they wrote, with rigorous reporting on conflicts ...

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.

As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech ...

Many focus on what weight-loss drugs take away: pounds. But they also offer patients something new: a sense of agency.

AI developer Nabla has raised $70 million as the company looks to expand the capabilities of its software that automates ...